Next-Generation Cancer Diagnostics: Technologies and Global Markets

Jun 2023| BIO081D| BCC Publishing

Report Highlights

The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.

Report Includes

  • 15 data tables and 80 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
  • Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
  • Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.

Report Scope

This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.

An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.

The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).

The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.

Frequently Asked Questions (FAQs)

The global market for next generation cancer diagnostics technologies and global market was valued at $7.8 billion in 2021. The market is forecast to grow at a compound annual growth rate (CAGR) of 11.5 % to reach $15 billion in 2027. In this report, the global market is segmented by type and region. By type, the market is segmented into products.
Cancer burdens patients, their families, the healthcare system, and society. The burden includes pain, suffering, and economic effects. Next-generation diagnostics can significantly help to reduce this burden at all stages of the disease, from early detection to diagnosis, therapy management, and monitoring, during and after treatment.
The Cancer site, Technology Platform, Purpose of Analysis and Test Platform products and technology market is segmented on the type and region. The type is further divided into products and Application.
Products segment will dominate the market by the end of 2027.
North America has the highest market share.
  • Abbott
  • Johnson & Johnson
  • Novartis
  • Roche
  • Termo fisher

Analyst Credentials

Kalyani Kottapenta – Assistant Manager, Life Sciences
Kalyani Kottapenta is a research professional with nine years of experience in the life sciences and healthcare industry. Her expertise in qualitative and quantitative market information, including market dynamics like market sizing, advanced excel based market modeling, data analysis, forecasting, company share analysis, and competitive landscape assessment of the medical device industry, developing custom reports. She holds a master’s degree in Microbiology and a bachelor’s in Biotechnology and Chemistry.

Report Synopsis

Report Metrics Details
Base year considered 2021
Forecast period considered 2022-2027
Base year market size $7.8 billion
Market size forecast $15 billion
Growth rate CAGR of 11.5% for the forecast period of 2022-2027
Units considered $ Millions
Segments covered Cancer Site, Purpose of Analysis, Test Platform, Region
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Companies studied
  • ABBOTT
  • ABBVIE INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • ARTIVION INC.
  • BD
  • BENITEC BIOPHARMA LTD.
  • CALADRIUS BIOSCIENCES
  • CELGENE CORP.
  • COMMENCE BIO
  • DEPUY SYNTHES (J&J)
  • DRAGERWERK AG & CO. KGAA
  • EPIC SCIENCES
  • GENEXINE INC.
  • GERON
  • ILLUMINA INC.
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • INEX INNOVATIONS EXCHANGE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC.
  • INVIVOSCRIBE INC.
  • MEDTRONIC
  • MERCK KGAA
  • NOVARTIS AG
  • ONCOCYTE CORP.
  • ONCOMED PHARMACEUTICALS INC.
  • PLURISTEM THERAPEUTICS INC.
  • SILICON BIOSYSTEMS S.P.A
  • SPHERE FLUIDICS
  • THERMO FISHER SCIENTIFIC INC.
  • VITATEX INC.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Next-Generation Cancer Diagnostics: Technologies and Global Markets166Free
Chapter- 1: Introduction8Free
Chapter- 2: Summary and Highlights4Free
Chapter- 3: Market and Technology Background20Free
Chapter- 4: Cancer Diagnostics Market25Free
Chapter- 5: Market Breakdown Application by Cancer Site40Free
Chapter- 6: Emerging Technologies4Free
Chapter- 7: Evaluation of the Market Based on Geographic Region10Free
Chapter- 8: Patents16Free
Chapter- 9: Company Profiles39Free
Published - Sep-2020| Analyst - John Bergin| Code - BIO081C

Report Highlights

The global market for next generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9% for the period of 2020-2025.

Report Includes

  • 22 data tables and 74 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
  • Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
  • Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
  • Details of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.
Published - Aug-2014| Analyst - John Bergin| Code - BIO081B

Report Highlights

BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.

Report Includes

  • An overview of the global market for next generation cancer diagnostics and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Analyses of the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic).
  • Examination of each technology format to determine its market status, impact on future market segments, and projected growth through the forecast period.
  • Discussion on factors influencing the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses.
  • Assessments of the major next generation formats that are likely to become commercialized within the next five years.
  • Profiles of companies in the industry as well as a look at corporate alliances.
Published - Apr-2011| Analyst - John Bergin| Code - BIO081A

Report Highlights

The total global annual market for next generation cancer diagnostics was $776 million in 2010, and is growing at a compound annual growth rate (CAGR) of 47%, to reach a forecast market size of $5.3 billion in 2015.

Next-Generation Cancer Diagnostics: Technologies and Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS